Monday, April 03, 2023 9:24:46 AM
It would seem to me that RLFTF needs to NOW focus on generating sales and turning a profit off of their existing portfolio of drugs. Rather than pay more salaries and bonuses for more R&D in gene therapy. Where are the $$ going to come from to pay this person. Is RAM's vision a never ending black hole of R&D. It's time to start generating sales and moving toward a profit making enterprise. They are about to do an R/S, and we know where that will take us a year down the road. More dilution to pay for initiatives such as this. JMHO.
Recent RLFTF News
- MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank • ACCESS Newswire • 03/19/2026 06:35:00 AM
- MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics • ACCESS Newswire • 12/23/2025 06:20:00 AM
- Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics • ACCESS Newswire • 12/15/2025 06:20:00 AM
- Relief Therapeutics Shareholders Approve Business Combination with NeuroX • ACCESS Newswire • 11/14/2025 05:40:00 PM
- Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 • ACCESS Newswire • 10/29/2025 06:20:00 AM
- Micro-Cap Biotech Skyrockets on FDA Pediatric Disease Nod • AllPennyStocks.com • 05/22/2025 04:49:00 PM
